TY - JOUR
T1 - Nitric oxide in primary headaches
AU - Thomsen, L L
AU - Olesen, J
PY - 2001/6
Y1 - 2001/6
N2 - The molecular mechanisms that underlie the primary headaches-migraine, cluster headache and tension-type headache-have not yet been clarified. On the basis of studies in headache induced by intravenous infusions of glyceryl trinitrate (an exogenous nitric oxide donor) and histamine (which liberates nitric oxide from vascular endothelium), it has been suggested that nitric oxide is a likely candidate responsible molecule. The present review deals with the biology of this small messenger molecule, and the updated scientific evidence that suggests a key role for this molecule in primary headaches. This evidence suggests that the release of nitric oxide from blood vessels, perivascular nerve endings or from brain tissue is an important molecular trigger mechanism in spontaneous headache pain. Pilot trials have shown efficacy of a nitric oxide synthase inhibitor in both migraine attacks and chronic tension-type headache. These observations suggest new approaches to the pharmacological treatment of headache.
AB - The molecular mechanisms that underlie the primary headaches-migraine, cluster headache and tension-type headache-have not yet been clarified. On the basis of studies in headache induced by intravenous infusions of glyceryl trinitrate (an exogenous nitric oxide donor) and histamine (which liberates nitric oxide from vascular endothelium), it has been suggested that nitric oxide is a likely candidate responsible molecule. The present review deals with the biology of this small messenger molecule, and the updated scientific evidence that suggests a key role for this molecule in primary headaches. This evidence suggests that the release of nitric oxide from blood vessels, perivascular nerve endings or from brain tissue is an important molecular trigger mechanism in spontaneous headache pain. Pilot trials have shown efficacy of a nitric oxide synthase inhibitor in both migraine attacks and chronic tension-type headache. These observations suggest new approaches to the pharmacological treatment of headache.
KW - Enzyme Inhibitors/therapeutic use
KW - Headache/drug therapy
KW - Humans
KW - Migraine Disorders/drug therapy
KW - Nitric Oxide/physiology
KW - Nitric Oxide Synthase/antagonists & inhibitors
U2 - 10.1097/00019052-200106000-00009
DO - 10.1097/00019052-200106000-00009
M3 - Review
C2 - 11371754
SN - 1350-7540
VL - 14
SP - 315
EP - 321
JO - Current Opinion in Neurology
JF - Current Opinion in Neurology
IS - 3
ER -